State Street’s Edesa Biotech EDSA Stock Holding History

State Street’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$199K	Buy	37,979 +19,300	+103%	+$57.9K	﹤0.01%	3889
2025 Q4	$27.1K	Buy	+18,679	New	+$36.6K	﹤0.01%	4219
2023 Q4	–	Sell	-6,282	Closed	-$27.5K	–	4453
2023 Q3	$27.5K	Hold	6,282	–	–	﹤0.01%	4404
2023 Q2	$35.2K	Hold	6,282	–	–	﹤0.01%	4501
2023 Q1	$40.1K	Hold	6,282	–	–	﹤0.01%	4555
2022 Q4	$95K	Buy	6,282 +2,828	+82%	+$21.1K	﹤0.01%	4384
2022 Q3	$22K	Hold	3,454	–	–	﹤0.01%	4816
2022 Q2	$39K	Buy	3,454 +186	+6%	+$2.74K	﹤0.01%	4771
2022 Q1	$68K	Hold	3,268	–	–	﹤0.01%	4736
2021 Q4	$129K	Buy	3,268 +1,286	+65%	+$61.5K	﹤0.01%	4512
2021 Q3	$102K	Buy	+1,982	New	+$77.1K	﹤0.01%	4539

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street's EDSA Position: Q1 2026 in Review

State Street increased its Edesa Biotech (EDSA) stake by 103% in Q1 2026, buying an estimated $57.9K and bringing the position to 37,979 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #3889.

State Street first reported a position in EDSA in Q3 2021 and has held it in 11 quarters since. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

State Street held 37,979 shares of Edesa Biotech worth $199K as of Q1 2026.
State Street bought 19,300 Edesa Biotech shares in Q1 2026, an estimated $57.9K.
Edesa Biotech made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3889 holding.
State Street first reported a position in Edesa Biotech in Q3 2021 and has held it in 11 quarters since.
28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.